Welcome to our dedicated page for Microbot Medical SEC filings (Ticker: MBOT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Microbot Medical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Microbot Medical's regulatory disclosures and financial reporting.
Microbot Medical Inc. director Madden Martin J. received a grant of stock options representing 10,000 shares of common stock. The options have an exercise price of $2.37 per share, were granted on April 1, 2026, and expire on April 1, 2036.
This is a compensation-related award, not an open-market purchase or sale, and leaves the director holding 10,000 options following the transaction.
Microbot Medical Inc. director Wenderow Tal Baruch received a grant of stock options, giving the right to buy 10,000 shares of common stock. The options have an exercise price of $2.37 per share and expire on April 1, 2036. Following this grant, Baruch holds stock options covering 10,000 shares directly.
Microbot Medical Inc. director David James Wilson received a grant of stock options covering 10,000 shares of common stock. The options were awarded at an exercise price of $2.37 per share, carry no upfront cost, and were granted on April 1, 2026.
These options give him the right to buy 10,000 shares of Microbot Medical common stock at $2.37 per share until their expiration on April 1, 2036. After this grant, he holds 10,000 stock options directly, with no additional derivative positions shown in this filing.
Microbot Medical Inc. director Burell Scott R reported receiving a grant of stock options. On April 1, 2026, he was awarded options to acquire 10,000 shares of common stock at an exercise price of $2.37 per share, expiring on April 1, 2036. Following this grant, he holds stock options covering 10,000 underlying shares directly.
Microbot Medical Inc. director Laxminarain Prattipati received a grant of stock options covering 10,000 shares of common stock. The options have an exercise price of $2.37 per share, were granted on April 1, 2026, and expire on April 1, 2036.
Following this grant, Prattipati holds stock options for 10,000 shares directly. This is a compensation-related award, not an open‑market purchase or sale of Microbot Medical common stock.
Microbot Medical provides an in-depth annual update on its transition from R&D to commercialization of the FDA‑cleared LIBERTY® Endovascular Robotic Surgical System, its sole product. The company began a limited U.S. market release in November 2025 and is planning a full launch around the Society of Interventional Radiology conference in April 2026.
LIBERTY is a compact, single‑use, remotely operated robotic system aimed at peripheral endovascular procedures, with telerobotic capabilities still under evaluation. Microbot reports no revenues through December 31, 2025 and continues to incur significant operating losses while investing heavily in R&D, manufacturing scale‑up and commercial infrastructure.
The company received ISO 13485:2016 certification in 2024 to support CE Marking, and anticipates CE Mark approval for LIBERTY in the second half of 2026, enabling European sales. Operations rely on third‑party manufacturing, Israeli government grants, and a 43‑person workforce in the U.S. and Israel, while management highlights ongoing capital needs and detailed risk factors, including geopolitical risks tied to recent Middle East hostilities.
Microbot Medical Inc. filed an update highlighting real-world use of its LIBERTY Endovascular Robotic System at Emory Healthcare. Emory’s interventional radiologists successfully performed robotic peripheral endovascular procedures, including the world’s first robotic prostatic artery embolization for benign prostatic hyperplasia and robotic Y-90 radioembolization mapping for liver cancer.
The LIBERTY System is described as the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, designed to enhance precision, reduce radiation exposure and physical strain, and improve procedural efficiency. Microbot began a Limited Market Release in November 2025 and plans a Full Market Release at the Society of Interventional Radiology conference in April 2026 to further drive adoption.
Microbot Medical Inc. reported that a pivotal clinical study of its LIBERTY® Endovascular Robotic System has been published in the peer‑reviewed Journal of Vascular and Interventional Radiology. The article analyzes the ACCESS-PVI multicenter feasibility study, whose lead principal investigator was Dr. Francois Cornelis.
The company notes that publication follows completion of the ACCESS-PVI study in 2025 and its presentation at the Society of Interventional Radiology meeting. LIBERTY received U.S. FDA clearance in September 2025 for peripheral endovascular procedures. Microbot began a limited market release in late 2025 and plans a full market release at the Society of Interventional Radiology conference in April 2026.
Microbot Medical Inc. furnished an 8-K to share that it will participate in the Roth Annual Growth Conference in Laguna Niguel, California from March 22-24, 2026. CEO Harel Gadot will join a live fireside Q&A on March 23, with a webcast available through the company’s website.
The company also released updated investor presentation materials, accessible online, highlighting progress with its LIBERTY Endovascular Robotic System. LIBERTY is described as the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, moving from a limited market release that began in late 2025 toward a planned full market release at the SIR conference in April 2026.
Microbot Medical Inc. filed a report to share that it will participate in the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference, held March 16–19, 2026. CEO, President and Chairman Harel Gadot will present live at 8:40 a.m. ET on March 19, 2026.
The company will highlight the expanding clinical experience and recent achievements from the limited market release of its LIBERTY Endovascular Robotic System. LIBERTY is described as the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. Microbot began a limited market release in late 2025 and plans a full market release at the Society of Interventional Radiology conference in April 2026.